Acambis Inc.

Oravax, Inc.

Oravax-merieux Co.

Sanofi Pasteur Biologics Co.

Sanofi Pasteur Biologics, LLC

Richard A Weltzin

Thomas P Monath

Farshad Guirakhoo

Harold Kleanthous

Bruno Guy

Samuel K Ackerman

Cynthia K Lee

Hitesh Bhagat

Gopalan Soman

Jacques Pappo

William D Thomas

Ilene Sussman

Thomas Ermak

The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.

Vaccinia virus strains

Smallpox vaccine

This invention provides methods of inducing a protective or therapeutic immune response to Helicobacter infection in a mammal by parenterally administering to the mammal one or more Helicobacter antigens and an adjuvant selected from one or more of LT, CT, LTB, and CTB.

LT and CT in parenteral immunization methods against helicobacter infection

Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Multimeric, recombinant urease vaccine

A new hybridoma cell line HNK20 which secretes a monoclonal IgA antibody to respiratory syncytial virus is disclosed. The antibody has diagnostic uses in respect of Respiratory Syncytial Virus.

Monoclonal IgA antibody specific for respiratory syncytial virus, a

Growing community of inventors

Lunenburg, MA, United States of America

Richard A Weltzin